Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Sagimet Biosciences announced positive 52-week data from Ascletis' Phase 3 open-label extension trial of denifanstat, an oral FASN inhibitor for moderate to severe acne vulgaris. The results demonstrated sustained efficacy with a 57% treatment success rate and significant reduction in lesion counts, while maintaining a favorable safety profile. Sag…